Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on Bio-Path in a research report on Wednesday. They set a "sell" rating on the stock. HC Wainwright lowered their price target on Bio-Path from $12.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, May 18th.
Bio-Path Stock Performance
Shares of BPTH Stock traded down $0.03 on Wednesday, reaching $4.10. 23,423 shares of the company's stock traded hands, compared to its average volume of 30,145. Bio-Path has a 12-month low of $2.68 and a 12-month high of $8.62. The company has a market capitalization of $29.36 million, a P/E ratio of -2.55 and a beta of 1.48. The business's 50 day moving average price is $3.88 and its two-hundred day moving average price is $3.58.
Bio-Path (NASDAQ:BPTH - Get Rating) last issued its quarterly earnings results on Tuesday, August 16th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the previous year, the company posted ($0.26) EPS. Research analysts predict that Bio-Path will post -1.89 earnings per share for the current year.